title: Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.
abstract: BACKGROUND
  Current information on the prognostic importance of body mass index (BMI) for patients with early breast cancer is based on a variety of equivocal reports. Few have data on BMI in relationship to systemic treatment.
  
  
  METHODS
  Patients (6792) were randomized to International Breast Cancer Study Group trials from 1978 to 1993, studying chemotherapy and endocrine therapy. BMI was evaluated with eight other factors: menopausal status, nodal status, estrogen receptor status, progesterone receptor status, tumor size, vessel invasion, tumor grade and treatment. BMI was categorized as normal (< or =24.9), intermediate (25.0-29.9) or obese (> or =30.0).
  
  
  RESULTS
  Patients with normal BMI had significantly longer overall survival (OS) and disease-free survival (DFS) than patients with intermediate or obese BMI in pairwise comparisons adjusted for other factors. Subset analyses showed the same effect in pre- and perimenopausal patients and in those receiving chemotherapy alone. When assessed globally and adjusted for other factors, BMI significantly influenced OS (P = 0.03) but not DFS (P = 0.12).
  
  
  CONCLUSIONS
  BMI is an independent prognostic factor for OS in patients with breast cancer, especially among pre-/perimenopausal patients treated with chemotherapy without endocrine therapy.
authors.affiliation: Department of Obstetrics and Gynecology, Inselspital, Bern, Switzerland. gilles.berclaz@insel.ch
authors.forename: G
authors.initials: G
authors.lastname: Berclaz
authors.forename: S
authors.initials: S
authors.lastname: Li
authors.forename: K N
authors.initials: KN
authors.lastname: Price
authors.forename: A S
authors.initials: AS
authors.lastname: Coates
authors.forename: M
authors.initials: M
authors.lastname: Castiglione-Gertsch
authors.forename: C-M
authors.initials: CM
authors.lastname: Rudenstam
authors.forename: S B
authors.initials: SB
authors.lastname: Holmberg
authors.forename: J
authors.initials: J
authors.lastname: Lindtner
authors.forename: D
authors.initials: D
authors.lastname: Erien
authors.forename: J
authors.initials: J
authors.lastname: Collins
authors.forename: R
authors.initials: R
authors.lastname: Snyder
authors.forename: B
authors.initials: B
authors.lastname: Thürlimann
authors.forename: M F
authors.initials: MF
authors.lastname: Fey
authors.forename: C
authors.initials: C
authors.lastname: Mendiola
authors.forename: I Dudley
authors.initials: ID
authors.lastname: Werner
authors.forename: E
authors.initials: E
authors.lastname: Simoncini
authors.forename: D
authors.initials: D
authors.lastname: Crivellari
authors.forename: R D
authors.initials: RD
authors.lastname: Gelber
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000401:mortality* / Q000628:therapy; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis